The ethics of CYP2D6 testing for patients considering tamoxifen

The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we...

Descripción completa

Detalles Bibliográficos
Autores principales: Hartman, Anne-Renee, Helft, Paul
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868921/
https://www.ncbi.nlm.nih.gov/pubmed/17433116
http://dx.doi.org/10.1186/bcr1663
_version_ 1782133411566059520
author Hartman, Anne-Renee
Helft, Paul
author_facet Hartman, Anne-Renee
Helft, Paul
author_sort Hartman, Anne-Renee
collection PubMed
description The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy.
format Text
id pubmed-1868921
institution National Center for Biotechnology Information
language English
publishDate 2007
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-18689212007-05-16 The ethics of CYP2D6 testing for patients considering tamoxifen Hartman, Anne-Renee Helft, Paul Breast Cancer Res Commentary The CYP2D6 gene is responsible for the majority of tamoxifen metabolism. Recent compelling, yet limited data have determined that postmenopausal women who carry a functional polymorphism in the CYP2D6 gene have a worse clinical outcome than women who have a wild-type genotype. In this commentary we discuss the level of evidence needed to change clinical practice and whether CYP2D6 genotyping is appropriate for all women considering tamoxifen as part of their adjuvant therapy. BioMed Central 2007 2007-04-13 /pmc/articles/PMC1868921/ /pubmed/17433116 http://dx.doi.org/10.1186/bcr1663 Text en Copyright © 2007 BioMed Central Ltd
spellingShingle Commentary
Hartman, Anne-Renee
Helft, Paul
The ethics of CYP2D6 testing for patients considering tamoxifen
title The ethics of CYP2D6 testing for patients considering tamoxifen
title_full The ethics of CYP2D6 testing for patients considering tamoxifen
title_fullStr The ethics of CYP2D6 testing for patients considering tamoxifen
title_full_unstemmed The ethics of CYP2D6 testing for patients considering tamoxifen
title_short The ethics of CYP2D6 testing for patients considering tamoxifen
title_sort ethics of cyp2d6 testing for patients considering tamoxifen
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1868921/
https://www.ncbi.nlm.nih.gov/pubmed/17433116
http://dx.doi.org/10.1186/bcr1663
work_keys_str_mv AT hartmanannerenee theethicsofcyp2d6testingforpatientsconsideringtamoxifen
AT helftpaul theethicsofcyp2d6testingforpatientsconsideringtamoxifen
AT hartmanannerenee ethicsofcyp2d6testingforpatientsconsideringtamoxifen
AT helftpaul ethicsofcyp2d6testingforpatientsconsideringtamoxifen

Ejemplares similares